Featuring perspectives from Dr Sara M Tolaney, including the following topics:
- Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00)
- First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13)
- First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02)
- Antibody-drug conjugates for previously treated HER2-low metastatic breast cancer (19:15)